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Abstract
Blood pressure (BP) is a complex trait that is regulated by multiple physiological pathways and include but is not limited to
extracellular fluid volume homeostasis, cardiac contractility, and vascular tone through renal, neural, or endocrine systems.
Uncontrolled hypertension (HTN) has been associated with an increased mortality risk. Therefore, understanding the genetics
that underpins and influence BP regulation will have a major impact on public health. Moreover, uncontrolled HTN has been
linked to inter-individual variation in the drugs’ response and this has been associated with an individual’s genetics architecture.
However, the identification of candidate genes that underpin the genetic basis of HTN remains a major challenge. To date, few
variants associated with inter-individual BP regulation have been identified and replicated. Research in this field has accelerated
over the past 5 years as a direct result of on-going genome-wide association studies (GWAS) and the progress in the identification
of rare gene variants and mutations, epigenetic markers, and the regulatory pathways involved in the pathophysiology of BP. In
this reviewwe describe and enhance our current understanding of how genetic variants account for the observed variability in BP
response in patients on first-line antihypertensive drugs, amlodipine and hydrochlorothiazide.
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Introduction
Hypertension (HTN) often called the Bsilent killer^ is defined
as a recurrent systolic/diastolic Blood pressure (BP) higher
than 140/90 mmHg. It affects approximately 1.13 billion peo-
ple with an estimated 7.5 million deaths globally [1]. Of great
concern is the 30–40% of working age adults (25–64 years of
age) that are hypertensive, and of which only one third have
their BP under control [1, 2]. Uncontrolled BP is associated
with increased risk for stroke and coronary artery disease,
which are the leading causes of death worldwide.
Hypertension has not only become a public health problem
but a key national and international priority as uncontrolled
HTN imposes a heavy cost on a country’s national budget,
health care services, and individual households. Similarly, in
Sub-Saharan Africa, HTN is classified as the number one
mortality risk with an estimated 500,000 deaths, affecting ap-
proximately 10 million South Africans with an associated 60–
75% uncontrolled cases [3, 4]. Furthermore, only 27% of
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treatment [5]. More alarmingly, HTN is a multifactorial dis-
ease that occurs in clusters with other diseases such as cardio-
vascular diseases and type 2 diabetes mellitus (T2DM) [4].
This is of great concern, as the latter two diseases contribute
to the exacerbating non-communicable disease burden.
Hypertension management and clinical
practice guidelines
Current interventions in the management and control of HTN
aim to reduce the mean BP of an individual, with the goal of
achieving consistent BP control. Thus, apart from diet and ex-
ercise, control of HTN can be achieved through patients’ adher-
ence to the prescribed anti-HTN drug therapy. Anti-HTN thera-
py includes the use of angiotensin-converting enzymes inhibi-
tors (ACEIs), angiotensin receptor blockers (ARBs), calcium
channel blockers (CCBs), and thiazide diuretics [6, 7]. These
prescribed drugs can be administered as a monotherapy, a two-
drug fixed-dose combination, or three-drug combination pill
with the aim to increase treatment adherence [2, 8–10].
However, according to the American Hypertension
Association, prescribed anti-HTN drugs should be administered
in the following combinations that are based on a drug’s effica-
cy, safety, and tolerability: (i) ACEI/CCB, (ii) ACE/thiazide
diuretic, (ii) ARB/CCB, and (vi) ARB/thiazide-type diuretic
[2]. Whereas, the combination of ACE with ARB is restricted
to use within the same regimen. The latter was confirmed in an
evidence-based recommendation review performed in 2014 by
medical consultants. The authors stated that an initial anti-HTN
monotherapy should include any of the prescribed anti-HTN
drugs, ACEIs, CCBs, ARBs, or thiazide diuretics but in a two-
drug therapy, while ACEIs and ARBs should not be adminis-
tered together [7]. They further stated that CCBs and thiazide
diuretics should be used as first-line therapies, particularly in the
Black population, as it has been associatedwith an improved BP
control in the African-American population [7]. The panel con-
tinued stating that if BP is not attained within the first month the
recommended drug dose should be increased. If neither mono-
therapy nor combination therapy works, a third drug should be
added, and the best triple fixed-dose combination include
amlodipine from the CCBs, valsartan from the ARBs, and hy-
drochlorothiazide (HCTZ) from the thiazide diuretics [11]. To
confirm this, various cross-sectional studies on the different clas-
ses of anti-HTN drugs and their effectiveness to control BP have
been investigated [12–14]. In a study done in 954 hypertensive
individuals and patients with T2DM, the authors confirmed that
the use of CCBs and thiazide diuretics was superior to any other
anti-HTN drug class [13]. A similar observation was made in a
longitudinal study conducted between January 2005 and April
2011 on 2780 uncontrolled HTN patients. The authors found
that different anti-HTN drug classes displayed different effects
on BP control, and that patients on CCBs and thiazide diuretics
showed a greater effect in lowering BP variability [12]. In addi-
tion, as CCBs and thiazides are the treatment of choice in the
African-American population, it has been proposed that treat-
ment therapy should be initiated with a low dose of thiazide
monotherapy and if BP is not achieved a CCB should be added.
This has been confirmed in the Jackson Heart Study where it
was found that although monotherapy with CCBs in the
African-American population is more effective, thiazide di-
uretics were more effective to obtain and sustain target BP
[15]. Needless to say, therapeutic interventions that investigated
the effects of mono or combination therapy on the control of BP
showed that a low-dose complementary treatment is more effec-
tive in reducing BPwith a response rate of 75–95% compared to
monotherapy. However, although effective, the efficacy of anti-
HTN mono or combination therapy is affected by race, gender,
age, and inter-individual variation, explaining the observed 60%
of HTN patients whose BP remain suboptimal and uncontrolled
even after rigorous treatment adherence [4, 14–18]. Thus, this
review will elaborate on single nucleotide polymorphisms
(SNPs) within drug metabolizing and transporter genes that
may contribute to the etiology of inter-individual differences in
BP response to two first-line HTN drugs, amlodipine andHCTZ.
Therefore, a systematic search on the association between single
nucleotide polymorphism, HTN, inter-individual variation, as
well as amlodipine andHCTZwas done by probingmajor search
engines and databases such as PubMed/Medline, EMBASE,
Cochrane Library Databases, Google Scholar and data submitted
to PharmGKB. The search was done from inception until end of
June 2018. The search included gray literature such as abstract
proceedings and pre-prints, while no language restrictions were
implemented, with review articles screened for primary findings.
Medical subject heading (MeSH) terms such as hypertension,
blood pressure, single nucleotide polymorphism, inter-
individual variation, amlodipine, and hydrochlorothiazide, in-
cluding corresponding synonyms and associated terms for each
item, were used.
Pharmacokinetics and mode of action
of first-line hypertensive drugs
Amlodipine
Amlodipine was introduced more than 35 years ago as a car-
diovascular drug [19]. This first-line long-acting 1-4-
dihydropyridine (DHP) CCB is known to control BP pressure
for 24 h, with minimum side effects. Amlodipine has been
shown to act by inhibiting the influx of calcium through L-
type calcium channels into vascular smooth muscle cells,
preventing vasoconstriction while simultaneously improving
blood flow. Amlodipine is prescribed at a daily dose of 5 and
10 mg, whereas the most commonly used derivative,
amlodipine besylate, is given at 6.9 mg and may reach
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bioavailability of 60–90% [19–21]. There are relatively small
fluctuations in plasma concentrations across a dosage interval
and the prescribed dose is effective for children aged 6 years,
whereas a starting dose of 2.5 mg is recommended for the
elderly [6, 19]. The pharmacokinetics (ADME; absorption,
distribution, metabolism, and elimination) of amlodipine have
been reviewed extensively, while its oral administration show
a linear dose-related pharmacokinetic profile (Table 1) [26].
Amlodipine is known to be highly bioavailable with a peak
plasma concentration at 6–12 h, reaching a steady state 7–
8 days after administration of the 5 mg/daily oral dose, with
low fluctuation and plasma concentration [2, 19, 22, 23].
Ninety percent of amlodipine is known to be bound to the
plasma membrane and the volume of distribution of
amlodipine is large (21 L/kg) [27]. Amlodipine is largely me-
tabolized in the liver via the Cytochrome P450 3A4/5
(CYP3A4/5) family of enzymes to its inactive form pyridine
metabolites (M9), after which M9 will undergo further oxida-
tive deamination to M10, O-demethylation to M1, and O-
dealkylation toM4 [22]. Once metabolized, the drug is slowly
eliminated for 40–60 h, with 10% of the parent compound and
60% of the metabolites excreted in the urine while fecal ex-
cretion account for 20–25% of the drug removal [19].
Hydrochlorothiazide
Thiazide and thiazide-like diuretics are one of the leading
drugs currently used for their antihypertensive properties.
Although HCTZ remains a drug of choice for HTN [28, 29],
its effective use as a monotherapy can be limited by various
factors, mainly those associated with inter-individual variation
[30, 31]. The limitations responsible for the reduced efficacy
of HCTZ contribute to the rapid rise in mortality in patients
with uncontrolled HTN [31]. Other main concerns relating to
the use of thiazides are usually their tendency to cause hypo-
kalemia, impair glucose tolerance, and abnormally elevate se-
rum cholesterol and uric acid levels [32]. HCTZ is orally ad-
ministered with the daily dosage ranging from 25 to 75 mg/
day, and an estimated bioavailability of 60–80% [33, 34]
(Table 2). It has been established that the gastrointestinal ab-
sorption of HCTZ is rapid and peak plasma concentration is
achieved at ~ 2 h, and its absorption is enhanced when it is
administered with food, with the majority of the drug
absorbed in the duodenum and the upper jejunum [34, 35].
HCTZ is transported ~ 40% bound to plasma proteins and it
can accumulate in erythrocytes. The ratio between the drug in
erythrocytes and plasma averages 3.5 and it has been reported
that the concentration of the drug in erythrocytes can be as
high as nine-fold the concentration in the plasma [37]. Limited
evidence exists concerning the metabolism of HCTZ; howev-
er, 2-amino-4-chloro-1,3-benzenedisulfonamide and chloro-
thiazide are some of the metabolites that have been detected
in urine after administration of this drug [36, 38, 39]. The half-
life of HCTZ is estimated to be 5 to 14 h, while the main
excretion route for this drug is through the kidneys [36]. In
addition, the mean renal clearance is ~ 300 mL/min and great-
er than 95% of the absorbed drug has been shown to be ex-
creted unchanged in urine (Table 2) [36].
Pharmacogenomics and inter-individual
variation of hypertensive drug therapy,
amlodipine and HCTZ
Variations in the human genome due to SNPs are believed to
be the most important cause of the variability in an individ-
ual’s drug response within a population. Genetic variation
frequencies differ between ethnic groups and could lead to
susceptibility to adverse drug reactions. This fact that drug
response is not universal is one of the main motivations be-
hind personalized medicine. The occurrence of adverse drug
reactions (ADRs) due to genetic differences in population is a
common phenomenon and is a huge public health concern as
it can exacerbate the conditions of the individual patient and
contribute to a strain on the health systems in terms of its
economic implications. In the USA, alone the cost of ADR-
Table 1 Pharmacokinetic properties of amlodipine
Pharmacokinetics Effect Reference
Bioavailability Amlodipine is orally administrated with a bioavailability of 64–90%. [2, 19, 22]
Absorption Amlodipine reach peak plasma concentration (tmax) 6–12 h after administration, while steady state plasma
concentrations will be reached within 7–8 days of daily dosing.
[2, 23]
Distribution Amlodipine has a high volume of distribution (21 L/kg) and a large proportion of the dose is distributed in
the tissue with ~ 90% of the circulating drug being bound to the plasma membrane.
[2, 22, 23]
Metabolism Amlodipine is extensively metabolized in the liver into its inactive metabolites via CYP3A4/5. [2, 22, 23]
Elimination Amlodipine is slowly cleared with an elimination half-life of 40 to 60 h. If discontinued, BP returned to baseline
after 1 week. Urine is the major route of elimination. Amlodipine is converted to inactive metabolites
(60%), which are excreted into the urine while 10% of the excreted drug remains unchanged.
Amlodipine is converted from dihydropyridinebmoiety to a pyridine derivative (M9). Fecal excretion accounts
for 20–25% of the dose
[2, 19, 22, 24, 25]
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related hospitalizations amounted to $136 billion in the last
few years (https://www.hcup-us.ahrq.gov/reports/statbriefs/
sb234-Adverse-Drug-Events.pdf-accessed 19 September
2018) of which antihypertensive contribute to 7.9%.
There are various other factors, which contribute to the
occurrence of ADRs and variation in drug responses in differ-
ent individuals. These include age, gender, other underlying
disease complications, nutrition, and co-medications to name
a few. Prescribing drugs with a potential co-interactions may
result in an ADR. However, when these factors are removed, a
substantial proportion of ADRs remain present due to a genet-
ic predisposition. The differences in ADR susceptibility in
ethnic populations have a big impact on the development of
drugs for any disease, where performing a clinical trial in one
population, that does not represent the complete target market,
might not produce the expected outcome. This is especially of
concern when most of the clinical trials are still performed in
the developed countries. Therefore, a population-based
pharmacogenomics approach is promising to address the issue
of ADRs in most settings by integrating the use of functional
SNPs and population-differentiated SNPs in drug develop-
ment and treatment. However, there are limitations to this
approach due to complexities that arises because researchers
will have to find the SNPs that are not only differently distrib-
uted among populations, but they also need to show functional
significance. In spite of this, the approach remains valuable in
addressing the issue of HTN in the different populations, as it
can still identify vulnerable individuals by using identified
SNPs linked to ADRs.
Numerous studies have reported on the genetic associations
of uncontrolled HTN and the effects thereof on treatment out-
come (Tables 3 and 4). These observations have not only en-
hanced our understanding of HTN and elaborated on mecha-
nisms by which amlodipine and HCTZ produce efficacy, but
have also contributed towards unraveling SNPs that may ac-
count for the observed differences in BP response to antihyper-
tensive agents. Furthermore, it is known that variation in genes
that code for drug metabolizing enzymes as well as drug trans-
porters plays an important role in the regulation and control of
HTN. Therefore, results from various genome-wide asso-
ciation studies (GWAS) studies concerning the effect of
genetic loci on the responsiveness of hypertensive patients
to amlodipine and HCTZ have been summarized in
Tables 3 and 4.
Genetic association and pharmacogenomics
of amlodipine response
The effect of calcium channel blockers in cardiac disease
was first pioneered by Fleckenstein and colleagues
(1983), using these drugs to reduce calcium influx into
the heart in order to improve contractile function without
impairing sodium dependent action potential [89]. As pre-
viously discussed, CCBs bind mainly to the L-type calci-
um cannels, which are located on the cardiac smooth mus-
cle cells, causing inhibition of calcium ions into vascular
smooth muscles leading to muscle relaxation and vasodi-
lation [90]. This decrease in vascular resistance is known
to reduce arterial BP with an associated decrease in HTN.
However, SNPs within these genes are known to influ-
ence the efficacy of these drugs. In particular, the β2-
regulatory subunit of the L-type calcium channel
(CCNB2), β1-adrenergic receptor (ADRB1), and family
of HECT domain E3 ubiquitin ligases (NEDD4L) have
been identified, through GWAS and pharmacogenomics,
as important genes in the regulation of BP in response to
anti-HTN drugs [91]. However, to date none of these has
been consistently replicated across studies [92].
Based on extracted data (Table 3), polymorphisms in genes
coding for enzymes involved in the metabolic break down of
amlodipine appear to play a major role in affecting its activity.
For example, scientific evidence has suggested that cyto-
chrome P450 family 3 subfamily Amember 5 (CYP3A5) gene
polymorphisms have significant association with anti-HTN
response in patients treated with amlodipine [40, 46, 49].
Cytochrome (CYP) P450 iso-enzymes are drug-
metabolizing enzymes that are known to play a pivotal role
in the metabolic clearance of amlodipine. The subfamily of
Table 2 Pharmacokinetic properties of hydrochlorothiazide
Pharmacokinetics Effect References
Bioavailability Oral administration of the drug ranges from 25 to 75 mg/day, and has a bioavailability of 60–80%. [34, 35]
Absorption Gastrointestinal absorption of the drug is rapid and peak plasma concentration is achieved at ~ 2 h. With the majority of
the drug is absorbed in the duodenum and the upper jejunum.
[34, 36]
Distribution The drug is transported ~ 40% bound to plasma proteins and it can also accumulate in erythrocytes. The ratio between
the drug in erythrocytes and plasma averages 3.5. Another report showed the concentration of the drug in
erythrocytes could be as high nine-fold to that of plasma.
[36, 37]
Metabolism Limited evidence exists related to the metabolism of this drug. However, 2-amino-4-chloro-1,3-benzenedisulfonamide
and chlorothiazide are some of the metabolites that have been detected in urine after administration of this drug.
[36–39]
Elimination The half-life of HCTZ is estimated to be 5 to 14 h. The main excretion route for this drug is the kidneys, with the mean
renal clearance of ~ 300 mL/min and greater than 95% of the absorbed drug shown to be excreted unchanged in
urine.
[33, 36]
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Table 3 Single nucleotide polymorphisms associated with BP response in genome-wide association analyses of amlodipine-treated patients
Gene SNP Treatment outcome Population References
ABCB1 rs1045642 Gender differences and SNPs in ABCB1 gene (2677G/T and
3435C/T) showed increased oral clearance of amlodipine.




For SNP rs200148 in the African-American cohort, the A allele
frequency is higher in the chlorthalidone treatment group as
compared to the amlodipine group.
Promoter mutations in rs4291 were associated with lower fasting






A significant reduction in BP was observed for the combined
presence of the identified SNPs (rs312481G/A and
rs3774426C/T).






Identified SNP 527974G/Awas able to decrease BP significantly
after treatment. However, none of the identified SNPs were
similar to those identified in the Brenner study.
Asian [43–45]
Estonian Genome Project found that patients with the combined





Blood pressure response was gender specific and associated with
African-American population with genotypes (16090T/C and
392 A/G).
African-American and [22, 42,
46–48]
Gender differences was observed but not significant and,
CYP3A5*3 does not affect amlodipine efficacy.
Asian
CYP3A5 rs776746 CYP3A5 6986A/G was not associated with decrease in BP response
in African-American population. But, a significant reduction in
BP occurred in Chinese and Korean cohort, CYP3A5*3/*3 car-
riers exhibited lower plasma amlodipine concentrations than
CYP3A5*1 carriers.
Gender differences was observed but not significant and,
CYP3A5*3 does not affect amlodipine efficacy.
African-American/Asian [46–49]
GNB3 rs5443 Splice variant is associated with the DBP lowering effect of
telmisartan but not amlodipine in Chinese.
Asian [50]
MDR1 G2677T/C3435T Discordant results with the C3435T found that the plasma drug
concentration of amlodipine in healthy volunteers of the MDR1
C3435T mutant allele carrier was lower than that of the CC type.
However, according to the study of Cai and colleagues, the
MDR1C3435Tmutant did not influence the effect of amlodipine
in renal transplant patients with hypertension. Therefore, further
investigations are required to elucidate the impact of the MDR1
C3435T polymorphism on the pharmacokinetics and efficacy of
amlodipine.
Caucasian and Asian [42, 51]
NOS1AP rs10494366 Significance (SNPs at this gene as relevant to stroke
pharmacogenetics.
African-American [52]
NPPA rs5065 The 2238T/C variant had lower event rates were for the C allele
carriers than for the TT homozygous when comparing
chlorthalidone and amlodipine. The AA genotype responds bet-
ter to amlodipine.
Multiple races and ethnic
groups
[53]
NUMA1 rs10898815 Increased response as determined by a greater decrease in DBP but
SBP blood pressure.
Multiple races and ethnic
groups
[44]
PICALM rs588076 Patients with the GG genotype and hypertensionmay have a greater
decrease in blood pressure.
Multiple races and ethnic
groups
[44]
POR rs1057868 1509 C/T genotypes had no significant impact on the blood drug
concentration and efficacy of amlodipine due to sample size.
Asian [42]
RYR3 rs877087 Reduced BP response was observed. Caucasian [54]
TANC2 rs2429427 Reduced BP response was observed. Multiple races [44]
ABCB1ATP-binding cassette subfamily B member 1, ACE angiotensin I converting enzyme, AGT angiotensinogen,CACN1D calcium channel voltage-
dependent, L type, alpha 1D subunit, CACNA1C calcium channel voltage-dependent, L type, alpha 1C subunit, CYP3A4 cytochrome P450 family 3
subfamily A member 4,CYP3A5 cytochrome P450 family 3 subfamily Amember 5,GNB3G Protein Subunit Beta 3,NOS1APNitric Oxide Synthase 1
Adaptor Protein, NPPA Natriuretic Peptide A, NUMA1 nuclear mitotic apparatus protein 1, PICALM phosphatidylinositol binding clathrin assembly
protein, POR cytochrome p450 oxireductase, RYR3 Ryanodine Receptor 3, TANC2 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2
Heart Fail Rev (2019) 24:343–357 347
Table 4 Single nucleotide polymorphisms associated with BP response in genome-wide association analyses of hydrochlorothiazide-treated patients
Gene SNP Treatment outcome Population References
ACE rs4303 BP response was altered by genotype. African-American [55]
ADD1 rs4961 BP response was altered by genotype carriers of the risk (T) allele. The Tcarriers











SNP in ADD1, WNK1, and NEDD4L, when present in combination, may have
significant effects on renal sodium handling, BP, and antihypertensive
response to thiazides.




T allele correlate with a higher incidence of uncontrolled hypertension and it is









ALDH1A3 rs3825926 SNP influenced response to hydrochlorothiazide treatment, 101445441A/G. Caucasian [67, 68]
ANKFN1 rs9915451 G allele has a decreased response to treatment in people with uncontrolled
hypertension compare to the A allele.
Caucasian [69]





AA genotype increased BP response to HCTZ compared to AT and TT
genotype.
Caucasian [69]
DOT1L rs2269879 SNP was strongly associated with greater SBP and DBP blood in Caucasians. Caucasian [71]
FBXL17 rs4431329 Patients with the AA genotype and essential hypertension may have an
increased response when treated with hydrochlorothiazide as compared to
patients with the AT or TT genotypes.
Caucasian [69]
FGF5 rs1458038 The T allele near FGF5 was associated with higher BP and higher risk for HTN
in Caucasian individuals. The authors found that the CC genotype better
respond to anti-HTN drugs compared to the TT and TC genotype. This SNP
was also strongly associated with BP in East Asians and South Asians and
only marginally in African-Americans. Caucasian hypertensive individuals






FTO rs4784333 C allele increased uric acid levels in subjects on HCTZ monotherapy plus
subjects who started treatment on atenolol and then had HCTZ added. Result
was not significant after Bonferroni correction.
African-American [75]








rs11065987 Representative SNP of rs11065987, rs653178, rs10774625, and rs11066301, all
of which are in high linkage disequilibrium with each other. The A allele of
rs11065987 was associated with a greater decrease in both systolic and
diastolic blood pressure following treatment with HCTZ compared to the GG
genotype.
Caucasian [77]
GPR83 rs3758785 The AA genotype may have increased response to hydrochlorothiazide in
people with essential hypertension as compared to patients with genotype GG
or AG.
African- American [78]
H3K4me1 rs11750990 SNP identified to be associated with SBP response in the GWAS meta-analysis
of Caucasians.




CC genotype associated with higher BP response and more significant in males.
TC haplotype of SNP rs3765945 and rs1047303 have been significantly
associated with SBP.
African-American [72]
KCNJ1 rs59172778 SNP increase fasting blood glucose levels. African-American
and Caucasian
[79, 80]
LUC7L2 rs6947309 SNP elevated in African-Americans but not Caucasians. African-American
and Caucasian
[75]





PRKCA rs16960228 BP responses were consistently greater in carriers of the A allele than in GG
homozygotes.
Caucasians [76, 83, 84]
SH2B3 rs3184504 The C allele (nonsynonymous, T/C, Trp/Arg) was associatedwith reduced BP in
Caucasians, whereas in African-Americans the C allele is associated with a
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P450 iso-enzymes, CYP3A4 and CYP3A5 genes, is highly
polymorphic and has been implicated in the observed varia-
tion in amlodipine response [93]. In addition, depending on
the population under study, CYP3A4/5 has been shown to
display ethnic differences and gender differences that may
affect the efficacy of amlodipine [42, 46, 47]. It has been
reported that the CYP3A4 genotype influences BP response
of amlodipine in the African-American population, while
CYP3A5 SNPs have been linked to Korean and Chinese sub-
jects [22, 46, 48, 49]. In the study conducted by Bhatnagar
et al. (2010), it was shown that CYP3A4 392A/G promoter
polymorphism was predictive of BP response among African-
American women, where women with an A allele were three
times more likely to reach a mean arterial pressure (MAP) of
107 mmHg [46]. This study suggests that the G allele carriers
were rapid metabolizers of amlodipine. However, the results
obtained from this study have been difficult to confirm in
other independent populations and ethnic groups as the G
allele at 392A/G has shown contradictory results pertaining
to drug dose requirements. However, most studies did not
examine the relationship in a gender-specific manner. The
authors further found that the effects of CYP3A4 392A/G ge-
notype on therapeutic response to amlodipine were not the
same in men and women, suggesting differential CYP activity
in the male versus female hormonal milieu. P-glycoprotein
(PgP) levels, a multidrug transporter that mediates cellular
transport of several drugs, have been shown to be two to three
times higher in men in comparison to women. P-glycoprotein-
mediated efflux of drugs such as amlodipine may result in
higher intracellular concentrations in women, resulting in
more variation in metabolism according toCYP3A4 genotype.
Furthermore, it has been reported that unlike CYP3A4,
CYP3A5 is highly polymorphic in Korean males (carriers)
with a CYP3A5*3/*3 genotypes displaying lower plasma
amlodipine concentration compared to the CYP3A5*1/*1 ex-
pressers, suggesting that CYP3A5 polymorphisms have an
effect on amlodipine disposition [48]. Nonetheless, conflict-
ing data has been presented regarding observed individual
variability to amlodipine and polymorphisms associated with
CYP3A4/5 genes. Though Kim et al. (2006) elegantly showed
that CYP3A5*3 polymorphism affects efficacy of amlodipine,
Guo and colleagues (2015) presented data showing that
CYP3A5*3 polymorphism has no impact on plasma concen-
tration and efficacy of amlodipine [42]. This was confirmed in
an in vitro study done on human liver microsomes where the
authors showed that CYP3A4 is primarily responsible for
amlodipine dehydrogenation, and that polymorphic expres-
sion of CYP3A5 does not affect the pharmacokinetic variabil-
ity of amlodipine [22]. Thus, to date no conclusive evidence is
able to link the CYP3A4/5 gene polymorphism across the
different population groups to the observed variation in BP
response and efficacy of amlodipine. Guo et al. (2015) also
Table 4 (continued)
Gene SNP Treatment outcome Population References
STK39 rs6749447 The A minor allele has been associated with 2.0 mmHg higher SBP and a
1.0 mmHg higher DBP.
Caucasian [85, 86]
TET2 rs12505746 SNP in GENRES cohort was associated with DBP, but not with SBP. Caucasian [69]
TTC6 rs177852 CC + CT are associated with increased response to HCTZ in people with HTN
as compared to genotype TT. As greater antihypertensive efficacy of HCTZ
was observed in Blacks compared to Whites.
African-American [72]










Haplotype (ATC) was more frequently observed in the African population was
more frequently observed in the African population, whereas the poor re-




ACE angiotensin I converting enzyme, ADD1 adducin 1, AGT angiotensinogen, AGTR1Angiotensin II Receptor Type 1,ANKFN1Ankyrin Repeat And
Fibronectin Type III Domain Containing 1,ALDH1A3 aldehyde dehydrogenase 1 family member A3, ARDB1 adrenoceptor beta 1,CDCACell Division
Cycle Associated Gene,CLIC5 chloride intracellular channel 5,CSMD1 CUB and Sushi multiple domains 1,CSMD3CUB and Sushi multiple domains
3, CYP11B2 Cytochrome P450 Family 11 Subfamily B Member 2, DIAPH3 Diaphanous Related Formin 3, DOT1L DOT1 Like Histone Lysine
Methyltransferase, EBF1 Early B Cell Factor 1, ERCC6L2 ERCC Excision Repair 6 Like 2, EDN3 endothelin 3, FBXL17 F-Box And Leucine Rich
Repeat Protein 17, FGF5 fibroblast growth factor 5,FOXA1 forkhead box A1 gene, FTO FTO, Alpha-Ketoglutarate Dependent Dioxygenase,GJA1 gap
junction protein α1 gene, Gly460Trp alpha-adducin, GNAS guanine nucleotide binding protein, alpha stimulating complex, GPR83 G Protein-Coupled
Receptor 83, GRK5 G Protein-Coupled Receptor Kinase 5, H3K27ac Histone H3K27 acetylase, H3K4me1 Histone H3K methylase, HS3ST4 Heparan
Sulfate-Glucosamine 3-Sulfotransferase 4, HSD3B1 hydroxy-delta-5-steroid dehydrogenase, 3 β- and steroid δ-isomerase 1 gene, HTN hypertension,
KCNJ1 potassium voltage-gated channel subfamily J member 1, LUC7L2 LUC7 Like 2, Pre-MRNA Splicing Factor, NEDD4L neural precursor cell
expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase, NELFCD negative elongation factor complexmember C/D, NOS3Nitric
Oxide Synthase 3, PRKCA protein kinase C alpha, RAD52 RAD52 Homolog, DNA Repair Protein, SBP systolic BP response, SH2B3 SH2B Adaptor
Protein 3, SLC12A3 solute carrier family 12 member 3, SLC25A31 Solute Carrier Family 25Member 31, SNP single nucleotide polymorphism, STK39
serine/threonine kinase 39, TCF7L2 Transcription Factor 7 Like 2, TET2 Tet methylcytosine dioxygenase 2, TTC6 Tetratricopeptide Repeat Domain 6,
UGGT2 UDP-Glucose Glycoprotein Glucosyltransferase 2, YEATS4 YEATS domain containing 4
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reported on genetic polymorphism in cytochrome p450
oxireductase (POR) and the effect of POR A-503V genetic
polymorphism on CYP activity to influence the plasma con-
centration of amlodipine. However, due to the limitation of the
sample size used in the study, the effect of the polymorphism
could not be confirmed.
Amlodipine has also been shown to affect the drug trans-
porter, ATP-binding cassette subfamily B member 1 (ABCB1)
[40, 41, 94]. The ABCB1 gene (also known as multi drug
resistance 1; MDR1) is a known drug efflux pump with a role
in the cellular accumulation of amlodipine. Not only do poly-
morphisms in this transporter affect amlodipine’s pharmaco-
kinetics, but expression of this gene is also known to be af-
fected by gender differences [40, 95]. In the latter study, the
authors concluded that males with polymorphisms in the
ABCB1 genes require higher concentration of amlodipine
compared to females. This study was on par with Kim and
colleagues (2007), who showed that polymorphism in the
ABCB1 gene influences bioavailability and causes reduced
plasma levels of amlodipine. Similarly, Zuo et al. (2014) ob-
served that the ABCB1 gene polymorphism C-3435T
(rs1045642) might affect the plasma concentration of
amlodipine in hypertensive patients in a Chinese Han popula-
tion. However, as previously stated, the authors concluded
that the polymorphisms did not have any impact on the effi-
cacy of amlodipine. As limited studies have been conducted
on the effect of the ABCB1 transporter, no association can be
made to the frequency of polymorphism in the anticipated
gene and the effect thereof amlodipine efficacy.
Similar to ABCB1, other SNPs, such as those specific for
the calcium channel, voltage-dependent, L type, alpha 1C
subunit (CACNA1C), have been shown to influence the effi-
cacy of amlodipine [45]. The authors investigated the efficacy
of various CCB (including amlodipine) on 120 Caucasian
subjects, diagnosed with HTN. Results obtained showed that
three variance in CACNA1C had a significant response to
amlodipine and felodipine, with rs2238032 and rs2239050
showing significant association with uncontrolled HTN.
However, due to small sample size and homogeneous popu-
lation, the authors concluded that results obtained, though
significant, requires a more heterogeneous population to be
confirmed. Furthermore, in a Japanese retrospective study co-
hort consisting of 48 randomly selected patients with con-
trolled and uncontrolled HTN, the authors screened the pro-
moter as well as all exons of the calcium channel, voltage-
dependent, L type, alpha 1D subunit (CACNA1D) and
CACNA1C genes. Three prominent SNP were identified
(rs312481 and rs3774426 linked to CACNA1D and
rs527974 linked to CACNA1C) conferring sensitivity to
amlodipine and other CCB in patients with uncontrolled
HTN [43, 44]. However, none of the identified SNPs were
similar to those identified in the Brenner study (2006).
Inferring that the SNPs identified in both studies were unique
to their respective population, and thus a larger heterogeneous
prospective study is needed to confirm the importance of these
SNP in uncontrolled HTN.
Some of the SNPs summarized in this review for which
greater information is still required to better inform of their
effect on influencing the efficacy of amlodipine
include phosphatidylinositol binding clathrin assembly
(PICALM), tetratricopeptide repeat, akyrin repeat and coiled-
coil containing 2 (TANC2), and nuclear mitotic apparatus pro-
tein 1 (NUMA). Briefly, in a GWAS performed on samples
obtained from patients that participated in the HOMED-BP
study [96], it was found that SNPs in three genes, PICALM,
TANC2, and NUMA, were associated with BP response to
amlodipine [44]. This study was replicated and the SNPs were
confirmed in the multicenter GEANE study on amlodipine
treatment [44]. However, this study must be interpreted within
the context of its potential limitation in that only 265 Japanese
patients were analyzed initially and this number decreased by
more than half upon replication of the study. Additional SNPs
identified are represented in Table 3.
Genetic association and pharmacogenomics of HCTZ
response
As previously mentioned, thiazide and thiazide-like diuretics
are currently considered first-line medications for the treat-
ment of HTN. However, like amlodipine, their therapeutic
efficacy can be hindered by inter-individual variation. For
instance, African-Americans and Caucasians with rs9943291
on 3-hydroxy-3-methylglutaryl-CoA synthase (HMGCS)
have been shown to present with elevated blood glucose levels
after treatment with both chlorthalidone and HCTZ [97, 98].
Although both these drugs are equally effective in managing
HTN [98], HCTZ is the more commonly prescribed thiazide
diuretic. Likewise, increasing studies, presented in Table 4,
have focused on identifying genomic variants associated with
HCTZ treatment. Although dosage-related side effects of
HCTZ are acknowledged, various factors such as inter-
individual differences, age, gender, and ethnicity play an im-
portant role in treatment outcome. For example, theα-adducin
(alpha-adducin) Gly460Trp polymorphism within the
angiotensin-converting enzyme (ACE) gene is linked to the
development of HTN and can predict the degree of inter-
individual response to HCTZ [55]. Pertaining to ethnic differ-
ences, African-Americans and Caucasians treated with 25 mg
per day of HCTZ showed a significant decreased BP after
correcting for both race and gender. However, in this study,
African-American females displayed a greater decline in
BP compared to the Caucasian females, inferring that racial
difference plays a role in BP control [99].
In a meta-analysis involving hypertensive European
Americans treated with HCTZ, it was demonstrated that ge-
netic variations in protein kinase C Alpha (PRKCA) and
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negative elongation factor complex member C/D (NELFCD)
were associated with DBP and SBP response, respectively
[76, 83]. Also, in a study done to identify gene loci that may
affect responsiveness of 228 male patients from European
decent on monotherapy on four classes of anti-HTN drugs
(HCTZ, amlodipine, bisoprolol, and losartan), > 80 SNPs
were identified [67]. Interestingly, the authors reported that
none of the identified SNP was common to more than a single
drug class and that the study was unable to identify
p h a rm a c o g e n om i c s a s s o c i a t i o n o f g e n om e -
wide significance, with the exception of three SNPs: aldehyde
dehydrogenase 1 family member A3 (ALDH1A3), chloride
intracellular channel 5 (CLIC5) and genes [67]. The identified
SNPs in ALDH1A3 (rs3825926) and CLIC5 (rs31329) are
known to influence HCTZ responsiveness, while variants in
the Nephrin (NPHS1) (rs3814995) gene influence losartan
treatment. Of interest, this study was performed in a
European cohort, and the authors stated that SNPs in two other
family members of the ADH gene (ALDH1A2 and ALDH7)
were found to be associated with the presence of HTZ in
African-Americans, while ALDH2 has been reported to be
associated with BP control in an East Asian population [67,
100, 101].
In recent years, GWAS studies conducted have identified
particular loci associated with BP response to HCTZ within
different ethnical groups [81, 87, 88]. In the African-American
populations, a region of chromosome 12q15 was associated
with HCTZ response. The haplotype analysis data suggested
that SNPs associated with lysozyme (LYZ), Yeast Domain
Containing 4 (YEATS4), and fibroblast growth receptor sub-
strate 2 (FRS2) had an effect on HCTZ response in these
patients [88]. This haplotype which was named ATC (a com-
bination on alleles for SNPs rs317689 (A), rs315135 (T), and
rs7297610(C)) was more frequently observed in the African-
American population who showed a good response to HCTZ,
whereas the poor responders had either an ACT or ATT hap-
lotype [88]. The SNP rs7297610 (C/T) had the most signifi-
cant association, and was considered to have the most notewor-
thy contribution to the observed phenotype. This association
was replicated in a study of 291 African and 294 Caucasian
individuals [81, 87]. In the PEAR study [81], the authors inves-
tigated the ATT haplotype and observed that the African-
American population had a good HCTZ response; however,
this was not observed in the Caucasian population. In addition,
there was a reduction in the levels of YEATS expression in
African-Americans after HCTZ treatment that were CC homo-
zygotes for the SNP rs7297610, and not in the Tcarriers, which
suggest a relationship between this YEATS variant and HCTZ
response [81, 87]. However, the study was not conclusive due
to the sample size used in this investigation.
According to Salvi et al. (2017), the following studies were
the largest collaborative studies conducted on the identifica-
tion of novel loci that influence BP response to HCTZ. The
major international study cohorts that contributed data to the
meta-analysis included the following: the GENRES study [67];
the GERA-1 study [99], the HCTZ-Milan study [69]; the
NORDIL study [82]; the PEAR-1; and the PHSS study [69].
The groups used a genome-wide meta-analysis approach, with
validation in the African population, and they identified two
candidate regulatory regions that were linked to the gap junction
protein α1 gene (GJA1) and forkhead box A1 gene (FOXA1),
two genes which were relevant to cardiovascular and kidney
function. In addition, they implored a gene-based approach,
from which they identified hydroxy-delta-5-steroid dehydroge-
nase, 3 β- steroid δ-isomerase 1 gene (HSD3B1) as being sig-
nificantly associated with BP response [72]. Multiple studies
have previously described the association of genetic variants in
HSD3B1 with HTN or BP variation [102–104]. The CC geno-
type at rs6203 was associated with HTN [105] and higher BP
[102–104]. The latter association was reported as being more
noteworthy in males and was confirmed by the authors’ single-
GWAS studies [72], while SNP rs3765945 and rs1047303 were
significantly associated with SBP [103, 104].
As previously stated, uncontrolled BP is a known risk for
cardiovascular dysfunction. Svensson-Farbon (2017) reported
on two genes demonstrating the strongest documented asso-
ciations between BP lowering and adverse cardiovascular out-
comes: neural precursor cell expressed, developmentally
down-regulated 4-like, E3 ubiquitin protein ligase
(NEDD4L) and ADRB1 with β-blockers. In NEDD4L, the
genetic polymorphism, rs4149601G/A, produces a cryptic
splice site in NEDD4L, with the G allele resulting in down-
regulation of the epithelial sodium channel (ENaC), thereby
increasing sodium retention/reabsorption, a process that is im-
portant for regulation of chronic HTN [82]. The authors report
that carriers of the G allele of this polymorphism (SNPs
rs4149601 and rs292499) were associated with a greater BP
lowering response to HCTZ when compared to the AA ho-
mozygotes (Svensson-Farbom et al., 2011). In addition, in-
creased risks for adverse cardiovascular outcomes were iden-
tified in Caucasians that were AG heterozygous for
rs4149601, and not treated with HCTZ. The hypothesis, that
patients with the rs4149601G/A polymorphism will exhibit a
greater response to thiazides, has been confirmed by an inde-
pendent study where the carries of G allele carriers were com-
pared to that of the AA genotype in a Caucasian population in
the PEAR-1 study [81]. However, further research is needed
to fully understand whether this polymorphism could be used
to guide treatment decisions in patients with HTN, as the
available data are certainly compelling.
For the gene PRKCA, the combined meta-analysis of data
obtained from the PEAR-1, GERA-1, NORDIL, and
GENRES studies, all displayed genome-wide significance
for rs16960228 [67, 76, 87]. Individuals who were carriers
of the A allele showed greater BP response to HCTZ then
the GG homozygote and had an increased level of PKRCA
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expression in Caucasians. The authors then continued and
investigated the contribution of other PRKCA SNPs to BP
response and found an additional SNP within the PRKCA
gene to be associated with BP control in African-American.
Pertaining to the PEAR study, three BP lowering alleles asso-
ciated with BP response to HCTZmonotherapy were identified
[74]. The three SNPs that were identified in the genes include
fibroblast growth factor 5 (FGF5—rs1458038), SH2BAdaptor
Protein 3 gene (SH2B3—rs3184504), and Early B Cell Factor
(EBF1—rs45551053) in a Caucasian population. The allele of
rs1458038 near FGF5 was associated with higher BP and in-
creased risk for HTN in Caucasian individuals [74]. The au-
thors found that the CC genotype responded better to anti-HTN
drugs compared to the TT and TC genotype. Gong (2012) also
reported that Caucasian hypertensive individuals with the T risk
allele for HTN might respond better to atenolol, than to HCTZ.
This SNP was also strongly associated with BP in East Asians
and only marginally in African-Americans [73]. Also, Gong
(2012) reported that the C allele (nonsynonymous, T/C, Trp/
Arg) in SH2B3 was associated with reduced BP in Caucasians,
but in African-Americans the C allele is associated with a slight
increase in blood [74].
In a 2013 GWAS study done by Turner et al. (2013), it was
shown that the GNAS–EDN3 region variant rs2273359 was sig-
nificantly associated with SBP response to HCTZ in the PEAR,
GERA, and NORDIL studies [76]. In the three studies, the avail-
able data indicated that carriers of the CG genotype at this locus
had an improved BP response to HCTZ than those with the CC
genotype. Additionally in a recent study performed by Sa and
colleagues (2018), the authors identified three genes, FBJmurine
osteosarcoma viral oncogene homolog (FOS), dual specificity
phosphatase 1 (DUSP1), and protein phosphatase 1 regulatory
subunit 15A (PPP1R15A), as potential molecular determinants
of antihypertensive response to thiazide diuretics [77]. The au-
thors found that the representative SNP of rs11065987,
rs653178, rs10774625, and rs11066301 were all in high linkage
disequilibrium with each other. An allele of rs11065987 was
associated with a greater decrease in both SBP and DBP com-
pared to the GG genotype following treatment with HCTZ. In a
GWAS performed in Amish individuals, the authors found a
strong association with common variants in a serine/threonine
kinase 39 (STK39) showing that variants in STK39 may influ-
ence BP by increasing STK39 expression and consequently al-
tering renal Na+ excretion, thus unifying rare and common BP-
regulating alleles in the same physiological pathway [86].
However, results obtained in most of these studies are in-
consistent and mostly conflicting due to issues relating to
population stratification, study design and sample size, expo-
sure to antihypertensive drugs, and the different methodolo-
gies used in the respective studies [78, 106, 107]. It is a well-
accepted fact that most of the cardiovascular-associated phe-
notypes, including HTN, are polygenic in nature as have been
demonstrated in individuals of European descent in a
multistage GWAS study that identified 29 previously known
or new SNP variants that influence BP [73]. This polygenic
nature is one of the biggest obstacles in identifying the most
appropriate SNPs associated with uncontrolled hypertensions
between different ethnic groups.
Similarly, in a study performed by Manunta (2008), the
authors identified three variants in genes that play a role in
the regulation of renal sodium absorption: α-adducin ADD1
(rs4961), WNK1 (rs880054 A/G), and NEDD4L (rs4149601
G/A). The identified genes have been associated with in-
creased BP; however, findings have been inconsistent.
However, the authors found that when individuals carry spe-
cific alleles of the three genes in combination, a marked re-
sponse to thiazide treatment could be observed [58–64].
Furthermore, additional SNP in candidate genes listed in
Table 4 has been shown to influence HCTZ response in hyper-
tensive patients and include alpha-adducin (ADD1; T allele car-
riers responded better to low-dose diuretic therapy) [56], rs5051
SNP in the promoter of the angiotensin gene (AGT) and the
linkage with rs699, which results in a M235T variant, also re-
ferred to as C4072T, has been associatedwith an increased risk of
hypertension in African-Americans compared to Caucasians.
However, the C allele in rs699 has been reported to be associated
with an increased risk of pregnancy-induced HTN (pre-
eclampsia) in Caucasians [57, 65]. Ankyrin-repeat and fibronec-
tin type III domain containing 1 (ANKFN1; G allele carriers have
a decreased response to HCTZ in Caucasians), Angiotensin II
type 1 receptor (AGTR1, A allele has an increased response to
HCTZ treatment in both African-Americans and Caucasians),
UDP-glucose glycoprotein glucosyltransferase 2 (UGGT2;
SNP rs9590353 was associated with a lower decrease in DBP
after HCTZ treatment), Calmodulin Ubiquitin (CUB) and Sushi
multiple domains 1 (CSMD1, Tallele has a decreased response to
HCTZ compared to A allele in Caucasians), Tet methylcytosine
dioxygenase 2 (TET2, A allele has a decreased response to
HCTZ compared to T allele in Caucasians), F-box and leucine
rich repeat protein (FBXL17, T allele has a decrease response to
HCTZ in Caucasians) [69]. SNPs associated with Luc7-like 2
(LUC7L2, SNP rs6947309 was associated with high BP in
African-Americans) Potassium inwardly-rectifying channel, sub-
family J, member 1 (KCNJ1, AG genotype associated with an
increased response to HCTZ compared to AA genotype in both
African-Americans andCaucasians) [79], tetratricopeptide repeat
domain 6 (TTC6, C allele has an increased response to HCTZ
compared to T allele), and alpha-ketoglutarate-dependent
dioxygenase gene (FTO, C allele carriers of rs4784333 following
HCTZ treatment showed an increased risk for hyperuriceamia in
African-Americans) has also been shown to affect HCTZ treat-
ment outcome [75].
Although alterations to most of these genes have been shown
to have a significant effect on the BP lowering effect in response
to HCTZ treatment, substantial evidence is still required to elab-
orate on the effect on inter-individual variation as very few of the
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SNPs identified have been replicated inmore than one study and/
or more than one population group. Therefore, further replica-
tions in other populations and functional studies are warranted to
improve our understating of the patients genetic profile and its
effect on drug treatment outcome.
Conclusion
The current data on genetic polymorphisms in HTN genetics
clearly indicates that no single genetic polymorphism with
very large effect size exists and it is therefore recommended
that two or more genes should be used to guide treatment
outcomes, however to date no such genes exist. It is further
recommended that a combination of modest effect size vari-
ants will probably need to be defined if we are to reach the
goal of genetic-guided antihypertensive therapy. However, al-
though our understanding of single gene effects on drug me-
tabolism is progressing, our comprehension of multiple gene
effects is very limited, and this complicates their use in diag-
nostics and improved treatment outcome. Therefore, despite
predictions that we are entering the realm of personalized
polymorphism-orientated drug therapy for most diseases in
the near future, HTN and other complex disorders will require
more extensive research before we reach that point.
Furthermore, numerous additional reports frequently associate
new SNPs with BP control, and some are removed as new
scientific information becomes available.
For examples, the most recent release of dbSNP (database
build 138) contains more than 38 million SNPs that span the
human genome (https://www.ncbi.nlm.nih.gov/projects/
SNP—accessed 20 September 2018). This creates an
enormous challenge to investigate the potential effect of
every SNP, despite the need to prioritize SNPs on the basis
of variables that are informative. One approach is so use a tag-
SNP approach (representative SNPs that are in high linkage
disequilibrium with other variants) as adopted by the
International HapMap Project and other GWAS studies [108,
109]. However, tag SNPs that are found to correlate with
differences in drug response is not always the causative
SNPs that are important for function of the drug-response
gene. Due to this fact that they could serve no functional
insight as pharmacogenetics prediction markers, one would
therefore still have to identify the potentially functional
SNPs in linkage disequilibrium with the tag SNPs. In addition
to this, these SNPs will still need to be validated experimen-
tally, and that is another major challenge to consider despite
the increase in SNP functional prediction algorithms.
In addition, to date the development of a SNP-chip for
HTN is still far off as literature curation of drug-response
genes requires an extensive collaborative effort and may be
subjected to a high error rate. The International Consortium
for Antihypertensive Pharmacogenomics Studies (ICAPS)
was created in 2012 to promote the collaboration among dif-
ferent research groups. The Consortium might facilitate the
identification and replication of pharmacogenetic findings
for the variability on antihypertensive drug response and
might reveal strong signals to be further used to guide treat-
ment selection (http://www.pharmgkb.org/page/icaps).
Together, these efforts may reveal new therapeutic strategies
and drug/dose optimization for HTN treatment. Furthermore,
the pre-emptive availability of genetic information in patient’s
medical records may favor the prescription based on genomic
information that might be more cost-effective than the trial
and error in current practice. The pharmacogenomics of anti-
hypertensive drugs is a field in progress and future efforts are
needed to unravel additional genes and variants, as well as
identify epigenetic and regulatory pathways involved in the
responsiveness to antihypertensive drugs. The potential of
pharmacogenomics to improve treatment of all disease, and
in particular uncontrolled HTN is enormous. The advantage of
screening an individual who have undesired side effects could
lead to an optimized treatment regimen that should assist in
the improvement of patient outcome and adherence to treat-
ment. However, the application of SNP genotyping and
haplotyping will not necessarily eradicate all problems asso-
ciated with treatment regiments, but could reduce the waste
associated with wrong treatment. As such, these applications
will also be useful in creating a pipeline for the treatment of
patients as new drugs are discovered and developed.
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